In a new wrinkle on the work being done to develop T-cell therapies to fight cancer, a group of investigators in Cleveland say they've seen promising lab results from a new adoptive approach that uses activated T cells extracted from the lymph nodes of melanoma patients.
San Diego's BioAtla has raised $30 million in equity from undisclosed Chinese investors, cash that will help push its pipeline of large-molecule treatments.
Drugmakers are quick to cite results from tests for new immuno-oncology meds, with companies screening for biomarkers in tumors to see which individuals would benefit from the drugs. But the tests are not always reliable and could leave out a subset of patients who are a good fit for the drugs, according to researchers.
There is no cure for genital herpes, but Genocea is getting closer to marketing an immunotherapy that could control herpes symptoms. The Massachusetts-based company announced Wednesday that it met its goals in a Phase II study of its investigational GEN-003 vaccine.
CAR-T contender Juno Therapeutics is settling in for the long haul in a race to commercialize new immunotherapies for cancer, buying up a European biotech to firm up its process on the way to late-stage development.
The stomach and the gut are difficult places for DNA to survive and eventually pass into the bloodstream intact. Now researchers have developed nanoparticle-coated bacteria that can someday be used to create effective DNA vaccines.
Aduro Biotech is picking up in 2015 where it left off last year, riding momentum into an upsized $119 million IPO to fund its breakthrough pancreatic cancer immunotherapy combo CRS-207 and GVAX.
Novartis and Juno Therapeutics, pioneers in a promising new field of cancer treatment, have reached a settlement in their long-running patent dispute, clearing the way for each to advance rival therapies designed to weaponize the immune system.
Kite Pharma, a leader among companies in the fast-moving field of cancer immunotherapy, is expanding its arsenal of potential treatments and making European landfall with a biotech buyout.
Food allergy upstart Allergen Research Corporation raised an $80 million B round to get its lead candidate into late-stage development, pushing ahead with a treatment for peanut allergies.